APPsα rescues Tau-induced synaptic pathology

• Verfasst von: Bold, Charlotte [VerfasserIn]
• Verfasst von: Baltissen, Danny [VerfasserIn]
• Verfasst von: Ludewig, Susann [VerfasserIn]
• Verfasst von: Back, Michaela K. [VerfasserIn]
• Verfasst von: Just, Jennifer [VerfasserIn]
• Verfasst von: Kilian, Lara [VerfasserIn]
• Verfasst von: Erdinger, Susanne [VerfasserIn]
• Verfasst von: Banićević, Marija [VerfasserIn]
• Verfasst von: Rehra, Lena [VerfasserIn]
• Verfasst von: Almouhanna, Fadi [VerfasserIn]
• Verfasst von: Nigri, Martina [VerfasserIn]
• Verfasst von: Wolfer, David Paul [VerfasserIn]
• Verfasst von: Spilger, Roman [VerfasserIn]
• Verfasst von: Rohr, Karl [VerfasserIn]
• Verfasst von: Kann, Oliver [VerfasserIn]
• Verfasst von: Buchholz, Christian J. [VerfasserIn]
• Verfasst von: Engelhardt, Jakob von [VerfasserIn]
• Verfasst von: Korte, Martin [VerfasserIn]
• Verfasst von: Müller, Ulrike C. [VerfasserIn]
• Titel: APPsα rescues Tau-induced synaptic pathology
• Verf.angabe: Charlotte S. Bold, Danny Baltissen, Susann Ludewig, Michaela K. Back, Jennifer Just, Lara Kilian, Susanne Erdinger, Marija Banicevic, Lena Rehra, Fadi Almouhanna, Martina Nigri, David P. Wolfer, Roman Spilger, Karl Rohr, Oliver Kann, Christian J. Buchholz, Jakob von Engelhardt, Martin Korte, and Ulrike C. Müller
• E-Jahr: 2022
• Jahr: 20 July 2022
• Umfang: 21 S.
• Fussnoten: Gesehen am 03.11.2022
• Titel Quelle: Enthalten in: The journal of neuroscience
• Ort Quelle: Washington, DC : Soc., 1981
• Jahr Quelle: 2022
• Band/Heft Quelle: 42(2022), 29, Seite 5782-5802
• ISSN Quelle: 1529-2401
• DOI: doi:10.1523/JNEUROSCI.2200-21.2022
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Alzheimer's disease
• Sach-SW: APPsα
• Sach-SW: hippocampus
• Sach-SW: interneurons
• Sach-SW: synaptic plasticity
• Sach-SW: Tau
• K10plus-PPN: 1820703290

Abstract

Alzheimer's disease (AD) is histopathologically characterized by Aβ plaques and the accumulation of hyperphosphorylated Tau species, the latter also constituting key hallmarks of primary tauopathies. Whereas Aβ is produced by amyloidogenic APP processing, APP processing along the competing nonamyloidogenic pathway results in the secretion of neurotrophic and synaptotrophic APPsα. Recently, we demonstrated that APPsα has therapeutic effects in transgenic AD model mice and rescues Aβ-dependent impairments. Here, we examined the potential of APPsα to mitigate Tau-induced synaptic deficits in P301S mice (both sexes), a widely used mouse model of tauopathy. Analysis of synaptic plasticity revealed an aberrantly increased LTP in P301S mice that could be normalized by acute application of nanomolar amounts of APPsα to hippocampal slices, indicating a homeostatic function of APPsα on a rapid time scale. Further, AAV-mediated in vivo expression of APPsα restored normal spine density of CA1 neurons even at stages of advanced Tau pathology not only in P301S mice, but also in independent THY-Tau22 mice. Strikingly, when searching for the mechanism underlying aberrantly increased LTP in P301S mice, we identified an early and progressive loss of major GABAergic interneuron subtypes in the hippocampus of P301S mice, which may lead to reduced GABAergic inhibition of principal cells. Interneuron loss was paralleled by deficits in nest building, an innate behavior highly sensitive to hippocampal impairments. Together, our findings indicate that APPsα has therapeutic potential for Tau-mediated synaptic dysfunction and suggest that loss of interneurons leads to disturbed neuronal circuits that compromise synaptic plasticity as well as behavior. - SIGNIFICANCE STATEMENT Our findings indicate, for the first time, that APPsα has the potential to rescue Tau-induced spine loss and abnormal synaptic plasticity. Thus, APPsα might have therapeutic potential not only because of its synaptotrophic functions, but also its homeostatic capacity for neuronal network activity. Hence, APPsα is one of the few molecules which has proven therapeutic effects in mice, both for Aβ- and Tau-dependent synaptic impairments and might therefore have therapeutic potential for patients suffering from AD or primary tauopathies. Furthermore, we found in P301S mice a pronounced reduction of inhibitory interneurons as the earliest pathologic event preceding the accumulation of hyperphosphorylated Tau species. This loss of interneurons most likely disturbs neuronal circuits that are important for synaptic plasticity and behavior.